Adherence to Treatment Recommendations for Chronic Obstructive Pulmonary Disease - Results from the Swedish National Airway Register
暂无分享,去创建一个
[1] Adherence to GOLD Recommendations among Swiss Pulmonologists and General Practitioners , 2020, COPD.
[2] M. Cazzola,et al. A case scenario study on adherence to COPD GOLD recommendations by general practitioners in a rural area of southern Italy: The "progetto PADRE". , 2020, Respiratory medicine.
[3] P. Dorinsky,et al. Triple Inhaled Therapy at Two Glucocorticoid Doses in Moderate-to-Very-Severe COPD. , 2020, The New England journal of medicine.
[4] A. Lindberg,et al. The Swedish National Airway Register (SNAR): development, design and utility to date , 2020, European clinical respiratory journal.
[5] E. Kerwin,et al. An Evaluation Of Single And Dual Long-Acting Bronchodilator Therapy As Effective Interventions In Maintenance Therapy-Naïve Patients With COPD , 2019, International journal of chronic obstructive pulmonary disease.
[6] C. Janson,et al. A Cross-Sectional Study Assessing Appropriateness Of Inhaled Corticosteroid Treatment In Primary And Secondary Care Patients With COPD In Sweden , 2019, International journal of chronic obstructive pulmonary disease.
[7] E. Kerwin,et al. Efficacy of umeclidinium/vilanterol versus umeclidinium and salmeterol monotherapies in symptomatic patients with COPD not receiving inhaled corticosteroids: the EMAX randomised trial , 2019, Respiratory Research.
[8] J. Vestbo,et al. Inhaled corticosteroid use by exacerbations and eosinophils: a real-world COPD population , 2019, International journal of chronic obstructive pulmonary disease.
[9] E. Wouters,et al. Contribution of individual COPD assessment test (CAT) items to CAT total score and effects of pulmonary rehabilitation on CAT scores , 2018, Health and Quality of Life Outcomes.
[10] P. Dorinsky,et al. Triple therapy with budesonide/glycopyrrolate/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, phase 3 randomised controlled trial. , 2018, The Lancet. Respiratory medicine.
[11] S. Rennard,et al. Predictors of exacerbation risk and response to budesonide in patients with chronic obstructive pulmonary disease: a post-hoc analysis of three randomised trials. , 2018, The Lancet. Respiratory medicine.
[12] M. Miravitlles,et al. Should Patients Switched from D to B in the GOLD 2017 Classification be Discontinued from Inhaled Corticosteroids? , 2017, COPD.
[13] A. Gayle,et al. Determinants of initial inhaled corticosteroid use in patients with GOLD A/B COPD: a retrospective study of UK general practice , 2017, npj Primary Care Respiratory Medicine.
[14] C. Janson,et al. Factors influencing pharmacological treatment in COPD: a comparison of 2005 and 2014 , 2017, European clinical respiratory journal.
[15] J. Wedzicha,et al. Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD. , 2016, The New England journal of medicine.
[16] A. Kaplan. Applying the wisdom of stepping down inhaled corticosteroids in patients with COPD: a proposed algorithm for clinical practice , 2015, International journal of chronic obstructive pulmonary disease.
[17] D. Price,et al. The inevitable drift to triple therapy in COPD: an analysis of prescribing pathways in the UK , 2015, International journal of chronic obstructive pulmonary disease.
[18] Dave Singh,et al. Tiotropium + olodaterol shows clinically meaningful improvements in quality of life. , 2015, Respiratory medicine.
[19] E. Kerwin,et al. Efficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trials. , 2014, The Lancet. Respiratory medicine.
[20] C. Stonham,et al. COPD Exacerbation Frequency, Pharmacotherapy and Resource Use: An Observational Study in UK Primary Care , 2013, COPD.
[21] F. Martinez,et al. Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials. , 2013, The Lancet. Respiratory medicine.
[22] F. Martinez,et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. , 2007, American journal of respiratory and critical care medicine.
[23] P. Calverley,et al. Maintenance therapy with budesonide and formoterol in chronicobstructive pulmonary disease , 2003, European Respiratory Journal.
[24] R. Sansores,et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease , 2003, European Respiratory Journal.
[25] tefan,et al. LONG-TERM TREATMENT WITH INHALED BUDESONIDE IN PERSONS WITH MILD CHRONIC OBSTRUCTIVE PULMONARY DISEASE WHO CONTINUE SMOKING , 2000 .
[26] D. Postma,et al. Long-Term Treatment with Inhaled Budesonide in Persons with Mild Chronic Obstructive Pulmonary Disease Who Continue Smoking , 1999 .
[27] P. Lange,et al. Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial , 1999, The Lancet.
[28] D. Postma,et al. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease. , 1999, The New England journal of medicine.